MEREO BIOPHARMA GROUP PLC
Get an alert when MEREO BIOPHARMA GROUP PLC files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Cash
£30M
-45.3% lowest in 3 filed years
Net assets
£38M
-36.8% lowest in 3 filed years
Employees
38
+11.8% highest in 3 filed years
Profit before tax
-£35M
-3.9% lowest in 3 filed years
Watchouts
Facts from the Companies House register and the latest accounts — not a rating
-
Material uncertainty over going concern
The Company's existing funds provide the Company with sufficient cash resources to meet its liabilities as they fall due and for the period to mid-2027. Therefore, although the Company continues to generate losses, the Directors consider that there is sufficient headroom between the forecast expenditure and cash resources such that the likelihood of the headroom being exhausted is remote.
-
Going-concern uncertainty disclosed
Net assets
3-year trend · vs Health Care median
Accounts
3-year trend · Δ = latest vs prior filed period · latest reflected 2025-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 | Δ vs prior |
|---|---|---|---|---|---|
| Turnover | £7,914,000 | £0 | £364,000 | — | |
| Operating profit | -£32,968,000 | -£35,831,000 | -£29,474,000 | +17.7% | |
| Profit before tax | -£34,647,000 | -£33,547,000 | -£34,858,000 | -3.9% | |
| Net profit | -£33,182,000 | -£32,256,000 | — | — | |
| Cash | £45,102,000 | £55,638,000 | £30,458,000 | -45.3% | |
| Total assets less current liabilities | £54,533,000 | £61,518,000 | £38,703,000 | -37.1% | |
| Net assets | £49,307,000 | £60,483,000 | £38,212,000 | -36.8% | |
| Equity | £49,307,000 | £59,566,000 | £38,184,000 | -35.9% | |
| Average employees | 34 | 34 | 38 | +11.8% | |
| Wages | £7,007,000 | £7,089,000 | £6,343,000 | -10.5% | |
| Directors' remuneration | £2,522,000 | £3,870,000 | £3,176,000 | -17.9% |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Return on capital employed | -60.5% | -58.2% | -76.2% | |
| Gearing (liabilities / total assets) | 21.1% | 17.0% | 8.8% | |
| Current ratio | 6.29x | 5.22x | 10.43x | |
| Interest cover | -20.08x | -47.02x | — |
Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.
Name history
Renamed 1 time since incorporation
- MEREO BIOPHARMA GROUP PLC 2016-06-03 → present
- MEREO BIOPHARMA GROUP LIMITED 2015-03-10 → 2016-06-03
Audit & accounting basis
- Accounting basis
- IFRS
- Reporting scope
- Consolidated group
- Auditor
- PricewaterhouseCoopers LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Material uncertainty disclosed
“The Company's existing funds provide the Company with sufficient cash resources to meet its liabilities as they fall due and for the period to mid-2027. Therefore, although the Company continues to generate losses, the Directors consider that there is sufficient headroom between the forecast expenditure and cash resources such that the likelihood of the headroom being exhausted is remote.”
Group structure
- MEREO BIOPHARMA GROUP PLC · parent
- Mereo BioPharma 1 Limited 100%
- Mereo BioPharma 2 Limited 100%
- Mereo BioPharma 3 Limited 100%
- Mereo BioPharma 4 Limited 100%
- Mereo BioPharma Ireland Limited 100%
- Mereo BioPharma 5, Inc. 100%
- Navi Subsidiary, Inc. 100%
- Mereo BioPharma Europe B.V. 100%
- Mereo US Holdings Inc. 100%
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
10 active · 13 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| SERMON, Charles Edward | Secretary | 2023-11-09 | — | — |
| BENDER, Jeremy, Dr | Director | 2020-10-01 | Sep 1971 | American |
| EKBLOM, Anders | Director | 2015-04-21 | Sep 1954 | Swedish |
| JACQUET, Pierre, Dr | Director | 2021-09-20 | Oct 1966 | Belgian |
| PAKIANATHAN, Deepika, Dr | Director | 2019-04-23 | Jan 1965 | American |
| ROBERTS, Justin | Director | 2022-11-10 | Oct 1982 | American |
| SCOTS-KNIGHT, Denise Vera, Dr | Director | 2015-03-10 | May 1959 | British |
| SHAMES, Daniel, Dr | Director | 2022-11-10 | Sep 1945 | American |
| WYZGA, Michael | Director | 2019-04-23 | Mar 1955 | American |
| YOSKOWITZ, Marc | Director | 2022-11-10 | Aug 1974 | American |
Show 13 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| COSTELLO, Simon James | Secretary | 2023-03-31 | 2023-11-08 |
| SERMON, Charles Edward | Secretary | 2015-05-19 | 2023-03-31 |
| ARMSTRONG, Frank Murdoch | Director | 2015-04-21 | 2019-02-08 |
| BAINS, Peter James Jonathan | Director | 2015-04-21 | 2021-09-20 |
| BLACKBURN, Paul | Director | 2015-10-06 | 2020-10-01 |
| BUNGAY, Richard Edward | Director | 2016-06-09 | 2016-11-01 |
| FELLNER, Peter John, Dr | Director | 2015-07-29 | 2022-11-10 |
| HYLAND, Anne Philomena | Director | 2022-03-01 | 2022-11-10 |
| JENKINS, Annalisa, Dr | Director | 2022-11-10 | 2026-05-14 |
| JONES, Richard Crispin | Director | 2017-01-30 | 2020-06-29 |
| KASHYAP, Kunal | Director | 2015-04-21 | 2021-10-26 |
| MULLICK, Abdul Hafeez, Dr | Director | 2022-05-17 | 2022-11-10 |
| SCHWARTZ, Brian, Dr | Director | 2020-10-01 | 2022-11-10 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Woodford Investment Management Limited | Corporate entity | Shares 25–50%, Voting 25–50% | 2016-06-09 | Ceased 2019-10-15 |
| Invesco Asset Management Limited | Corporate entity | Shares 25–50%, Voting 25–50% | 2016-06-09 | Ceased 2019-04-23 |
Filing timeline
Last 20 of 171 total filings
Material constitutional events — rename, articles re-file, resolution
- 2026-06-01 RESOLUTIONS Resolution
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-06-01 | RESOLUTIONS | resolution | Resolution | |
| 2026-05-27 | TM01 | officers | Termination director company with name termination date | |
| 2026-05-26 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2026-05-20 | AA | accounts | Accounts with accounts type group | |
| 2026-05-14 | SH01 | capital | Capital allotment shares | |
| 2026-05-09 | RP01AP01 | officers | Replacement filing of director appointment with name | |
| 2026-03-17 | RP01SH01 | miscellaneous | Legacy | |
| 2026-03-13 | SH01 | capital | Capital allotment shares | |
| 2026-03-12 | CH01 | officers | Change person director company with change date | |
| 2026-03-12 | CH01 | officers | Change person director company with change date | |
| 2026-02-23 | SH01 | capital | Capital allotment shares | |
| 2025-10-24 | SH01 | capital | Capital allotment shares | |
| 2025-07-30 | SH01 | capital | Capital allotment shares | |
| 2025-07-01 | CH01 | officers | Change person director company with change date | |
| 2025-06-11 | AA | accounts | Accounts with accounts type group | |
| 2025-03-28 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2025-03-20 | CH01 | officers | Change person director company with change date | |
| 2025-03-13 | AD02 | address | Change sail address company with old address new address | |
| 2025-02-27 | SH01 | capital | Capital allotment shares | |
| 2024-11-26 | SH01 | capital | Capital allotment shares |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 14
- Capital events
- 7
- Officers appointed
- 0
- Officers resigned
- 1
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.